{"id":50867,"date":"2022-01-13T15:50:17","date_gmt":"2022-01-13T14:50:17","guid":{"rendered":"https:\/\/cri1149.fr\/?post_type=publications&#038;p=50867"},"modified":"2025-09-11T16:48:00","modified_gmt":"2025-09-11T14:48:00","slug":"cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis","status":"publish","type":"publication","link":"https:\/\/cri1149.fr\/en\/publication\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\/","title":{"rendered":"CD62L on blood basophils: a first pre-treatment predictor of remission in severe lupus nephritis"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false},"category_publication":[],"class_list":["post-50867","publication","type-publication","status-publish","hentry"],"acf":{"numero_de_publication":"Nephrol Dial Transplant.","date_de_publication":"20211202","numero_doi":"","equipe":[101],"auteurs-liste":[{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]Matthieu Halfon[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]Delphine Bachelet[:]"},{"texte_libre":false,"auteur-lien":13239,"auteur-text":""},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]Barbara Dema[:]"},{"texte_libre":false,"auteur-lien":14855,"auteur-text":""},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]Pauline Manchon[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]Cedric Laouenan[:]"},{"texte_libre":false,"auteur-lien":13051,"auteur-text":""},{"texte_libre":false,"auteur-lien":13058,"auteur-text":""}],"auteurs-manuel":"","liens_externes":null,"liens":[{"lien":"https:\/\/pubmed.ncbi.nlm.nih.gov\/33316058\/"}],"paragraphe":"<h2 class=\"title\" style=\"text-align: justify;\">Abstract<\/h2>\r\n<div id=\"enc-abstract\" class=\"abstract-content selected\">\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Background:\u00a0<\/strong>Basophils were recently shown to contribute to lupus nephritis (LN). This study assessed blood basophil activation markers (BAMs) for the diagnosis of LN severity and as pre-treatment prognostic markers of the response to treatment in patients with severe LN.<\/p>\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Method:\u00a0<\/strong>The diagnostic study included all the patients of a monocentric prospective observational cohort built with consecutive patients diagnosed with LN on the basis of a renal biopsy. The prognostic study selected patients of this cohort according to the following inclusion criteria: \u226518 years old, Class III or IV A \u00b1 C \u00b1 Class V or pure Class V LN at the time of inclusion and treated with an induction treatment for LN. Clinical data and BAMs were obtained at the time of the kidney biopsy. LN remission status was recorded 12 months after induction therapy initiation. Associations between baseline data and histological severity of LN or LN remission were assessed using logistic regression.<\/p>\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Results:\u00a0<\/strong>No significant association was found between BAMs and the histological severity of LN in 101 patients. Among the 83 patients included in the prognostic study, 64 reached renal remission. CD62L expression on blood basophils at baseline was independently negatively associated with remission at 12 months [odds ratio = 0.26, 95% confidence interval 0.08-0.82, P = 0.02 for quantitative CD62L expression &gt;105 (geometric fluorescent intensity) gMFI]. CD62L &lt;105 gMFI was associated with a probability of 0.87 of LN remission in the next 12 months after the start of induction therapy.<\/p>\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Conclusion:\u00a0<\/strong>Pre-treatment CD62L expression on blood basophils could be a first predictive biomarker of renal response to induction therapy at 12 months in patients with severe LN.<\/p>\r\n<\/div>","paragraphe_en":"<h2 class=\"title\" style=\"text-align: justify;\">Abstract<\/h2>\r\n<div id=\"enc-abstract\" class=\"abstract-content selected\">\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Background:\u00a0<\/strong>Basophils were recently shown to contribute to lupus nephritis (LN). This study assessed blood basophil activation markers (BAMs) for the diagnosis of LN severity and as pre-treatment prognostic markers of the response to treatment in patients with severe LN.<\/p>\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Method:\u00a0<\/strong>The diagnostic study included all the patients of a monocentric prospective observational cohort built with consecutive patients diagnosed with LN on the basis of a renal biopsy. The prognostic study selected patients of this cohort according to the following inclusion criteria: \u226518 years old, Class III or IV A \u00b1 C \u00b1 Class V or pure Class V LN at the time of inclusion and treated with an induction treatment for LN. Clinical data and BAMs were obtained at the time of the kidney biopsy. LN remission status was recorded 12 months after induction therapy initiation. Associations between baseline data and histological severity of LN or LN remission were assessed using logistic regression.<\/p>\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Results:\u00a0<\/strong>No significant association was found between BAMs and the histological severity of LN in 101 patients. Among the 83 patients included in the prognostic study, 64 reached renal remission. CD62L expression on blood basophils at baseline was independently negatively associated with remission at 12 months [odds ratio = 0.26, 95% confidence interval 0.08-0.82, P = 0.02 for quantitative CD62L expression &gt;105 (geometric fluorescent intensity) gMFI]. CD62L &lt;105 gMFI was associated with a probability of 0.87 of LN remission in the next 12 months after the start of induction therapy.<\/p>\r\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Conclusion:\u00a0<\/strong>Pre-treatment CD62L expression on blood basophils could be a first predictive biomarker of renal response to induction therapy at 12 months in patients with severe LN.<\/p>\r\n<\/div>","documents":null},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CD62L on blood basophils: a first pre-treatment predictor of remission in severe lupus nephritis - CRI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cri1149.fr\/publication\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CD62L on blood basophils: a first pre-treatment predictor of remission in severe lupus nephritis - CRI\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cri1149.fr\/publication\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\/\" \/>\n<meta property=\"og:site_name\" content=\"CRI\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-11T14:48:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/publication\\\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\\\/\",\"url\":\"https:\\\/\\\/cri1149.fr\\\/publication\\\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\\\/\",\"name\":\"CD62L on blood basophils: a first pre-treatment predictor of remission in severe lupus nephritis - CRI\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#website\"},\"datePublished\":\"2022-01-13T14:50:17+00:00\",\"dateModified\":\"2025-09-11T14:48:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/publication\\\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cri1149.fr\\\/publication\\\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/publication\\\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/cri1149.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\\\/\\\/cri1149.fr\\\/publications\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CD62L on blood basophils: a first pre-treatment predictor of remission in severe lupus nephritis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#website\",\"url\":\"https:\\\/\\\/cri1149.fr\\\/\",\"name\":\"CRI - Centre de Recherche sur l'Inflammation\",\"description\":\"Centre de Recherche sur l&#039;Inflammation\",\"publisher\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cri1149.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#organization\",\"name\":\"CRI1149\",\"url\":\"https:\\\/\\\/cri1149.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cri1149.fr\\\/wp-content\\\/uploads\\\/2014\\\/11\\\/8.4.2014-logo-CRI.jpg\",\"contentUrl\":\"https:\\\/\\\/cri1149.fr\\\/wp-content\\\/uploads\\\/2014\\\/11\\\/8.4.2014-logo-CRI.jpg\",\"width\":215,\"height\":176,\"caption\":\"CRI1149\"},\"image\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/CRI-Centre-de-recherche-sur-linflammation-100116118884153\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/cri-centre-de-recherche-sur-l-inflammation\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CD62L on blood basophils: a first pre-treatment predictor of remission in severe lupus nephritis - CRI","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cri1149.fr\/publication\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\/","og_locale":"en_US","og_type":"article","og_title":"CD62L on blood basophils: a first pre-treatment predictor of remission in severe lupus nephritis - CRI","og_url":"https:\/\/cri1149.fr\/publication\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\/","og_site_name":"CRI","article_publisher":"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153","article_modified_time":"2025-09-11T14:48:00+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cri1149.fr\/publication\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\/","url":"https:\/\/cri1149.fr\/publication\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\/","name":"CD62L on blood basophils: a first pre-treatment predictor of remission in severe lupus nephritis - CRI","isPartOf":{"@id":"https:\/\/cri1149.fr\/#website"},"datePublished":"2022-01-13T14:50:17+00:00","dateModified":"2025-09-11T14:48:00+00:00","breadcrumb":{"@id":"https:\/\/cri1149.fr\/publication\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cri1149.fr\/publication\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cri1149.fr\/publication\/cd62l-on-blood-basophils-a-first-pre-treatment-predictor-of-remission-in-severe-lupus-nephritis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cri1149.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/cri1149.fr\/publications\/"},{"@type":"ListItem","position":3,"name":"CD62L on blood basophils: a first pre-treatment predictor of remission in severe lupus nephritis"}]},{"@type":"WebSite","@id":"https:\/\/cri1149.fr\/#website","url":"https:\/\/cri1149.fr\/","name":"CRI - Centre de Recherche sur l'Inflammation","description":"Centre de Recherche sur l&#039;Inflammation","publisher":{"@id":"https:\/\/cri1149.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cri1149.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cri1149.fr\/#organization","name":"CRI1149","url":"https:\/\/cri1149.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cri1149.fr\/#\/schema\/logo\/image\/","url":"https:\/\/cri1149.fr\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg","contentUrl":"https:\/\/cri1149.fr\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg","width":215,"height":176,"caption":"CRI1149"},"image":{"@id":"https:\/\/cri1149.fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153","https:\/\/www.linkedin.com\/company\/cri-centre-de-recherche-sur-l-inflammation\/"]}]}},"_links":{"self":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/publication\/50867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/types\/publication"}],"acf:term":[{"embeddable":true,"taxonomy":"equipes","href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/equipes\/101"}],"wp:attachment":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/media?parent=50867"}],"wp:term":[{"taxonomy":"category_publication","embeddable":true,"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/category_publication?post=50867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}